Your browser is no longer supported. Please, upgrade your browser.
Settings
XBI SPDR S&P Biotech ETF daily Stock Chart
XBI [NYSE]
SPDR S&P Biotech ETF
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand- Perf Week3.80%
Market Cap- Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month11.26%
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter2.57%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio4.16 Perf Half Y7.30%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-32.63%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range44.12 - 89.82 Perf YTD-15.46%
Dividend0.33 P/FCF- EPS past 5Y- ROI- 52W High-33.98% Beta-
Dividend %0.56% Quick Ratio- Sales past 5Y- Gross Margin- 52W Low34.39% ATR1.54
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)62.04 Volatility2.37% 2.66%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.60 Prev Close58.90
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume7.10M Price59.30
Recom- SMA206.43% SMA507.19% SMA2001.99% Volume4,262,362 Change0.68%
Jul-22-16 01:12PM  Will Orenitram Lose Market Share to Uptravi in 2016?
Jul-21-16 12:00PM  Is biotech back?
Jul-19-16 04:21PM  Earnings Estimates for These 3 Biotech Giants Should Be Heading Lower -- Here's Why at Motley Fool
Jul-18-16 11:07AM  How Much Potential Does Promacta Hold?
Jul-14-16 01:11PM  Ligand Pharmaceuticalss Performance Based on EV-to-EBITDA
11:05AM  ALNY Reports Positive Results from Open Label Extension Study of Revusiran
Jul-13-16 02:35PM  New Stock Market Highs Fighting Many More Outside Pressures Than Usual: Time to Panic? at 24/7 Wall St.
09:00AM  Biotech ETFs: Will the Once Hot Group Rebound?
Jul-07-16 12:18PM  Strong ISM Non-Manufacturing PMI Overshadows Services PMI
Jul-05-16 11:05AM  AbbVies Tests of Imbruvica with Venclexta for Oncology Therapy
Jul-01-16 04:06PM  Biotech Bottom Calls After Big Bounce (IBB, XBI) at Investopedia
11:07AM  What Are the Benefits of the Novartis-Xencor Alliance to Xencor?
07:01AM  Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here
Jun-30-16 06:33PM  Biotechs Building Base?...Or Bursting Bubble?
03:54PM  How Did Investors Respond to the Novartis-Xencor Alliance?
03:54PM  The Novartis-Xencor Collaboration Agreement: The Details
02:21PM  Hedge Funds Like ETFs Too
08:21AM  US Inflation Numbers Are Decent, Brexit Clouds Future Outlook
Jun-29-16 07:00AM  US GDP and Consumer Confidence: Is a Revival Coming?
Jun-26-16 07:21AM  The 5 Best Healthcare ETFs at Motley Fool
Jun-24-16 09:56AM  Brexit means little for biotech stocks, analyst says at MarketWatch
Jun-22-16 02:07PM  Traders Get It Right (Sort Of) With Leveraged Biotech ETFs
Jun-21-16 01:09PM  Bio Tech; Market leader testing breakdown level
Jun-16-16 10:46AM  Why Does XBIs Loss Continue to Widen?
Jun-15-16 11:50AM  Biotech: It's the Election, Silly at Barrons.com
09:16AM  Cellectar's stock soars after positive results of a study of its tumor treatment at MarketWatch
Jun-14-16 03:32PM  Biotech: Still Troubled at Barrons.com
07:00AM  IBB & XBI: Should You Short the Biotech Industry? at Investopedia
Jun-13-16 02:00PM  3 Cases When Not to Place Tight Stop-Loss Orders (IBB, XBI) at Investopedia
09:06AM  How Are XBIs Holdings Moving Averages Trending?
Jun-10-16 03:58PM  Downside Ahead For Biotech Stocks?
Jun-07-16 12:44PM  Yellen Upbeat on Economy: Wining Sector ETFs
12:33AM  Biotech Bounce: Sizzle Or Fizzle?
Jun-06-16 03:34PM  How Did Biotech ETFs Perform in the Week Ended June 3?
07:47AM  Exelixis's stock surges after positive results from trial of kidney cancer treatment at MarketWatch
Jun-03-16 01:20PM  The buzz from ASCO
11:22AM  ADP Unemployment Change Decent: Initial Jobless Claims Fall
09:06AM  Heres What Else Is Happening Now for Ionis
08:00AM  Trying to Believe in Biotech ETFs
Jun-02-16 04:08PM  6 Biotechs Seriously on the Move at 24/7 Wall St.
10:23AM  Biotech Stocks: Don't Expect a 'Miraculous Recovery' at Barrons.com
07:51AM  A.M. Funds Roundup: DoubleLine Hits $100B; Big Trading in Small-Cap Index Funds at Barrons.com
Jun-01-16 06:07PM  Inside Ioniss Key Pipeline Drug IONIS-TTR
09:23AM  3 High-Growth ETFs to Supercharge Your Portfolio at Motley Fool
May-31-16 05:58PM  What Happened to Ioniss Revenues in 1Q16?
03:26PM  A Lesson in Biotech Risk at Barrons.com
09:21AM  XBI Tops the Biotechnology ETFs in the Last Week of May
May-27-16 02:05PM  XBI Mid-Caps: Seattle Genetics Rose Due to Higher Trading Volumes
01:11PM  This Biotech ETF Could Be Ready To Party
01:02PM  3 Highly Rated IBD Stocks Powering A Top Biotech ETFs Revival
May-23-16 05:44PM  Markets Rise as Fed Member James Bullard Exhibits Hawkish Stance
May-19-16 12:16PM  XBI Large-Caps: Why Is BioMarin Inching Higher?
12:16PM  Markets Are Defensive: XBI Outperforms the Market
May-17-16 11:40AM  Biotech ETFs Soar on Pfizer-Anacor Deal: SBIO, XBI in Lead
May-16-16 10:07AM  Analyzing XBI Mid-Caps: Intrexon Fell Due to 1Q16 Loss
10:06AM  What Do Analysts Recommend for Medivation?
May-13-16 04:48PM  What Lies Ahead for Biotech ETFs?
May-12-16 12:13PM  Inside XBI Large-Caps: European Commission Approves of Empliciti
12:13PM  XBI Dropped, Markets Fell Due to Retail Sector Concerns
May-10-16 04:13PM  Why Did Medivations Share Price Increase so Much after Earnings?
07:00AM  The Trader Daily: Lots of Stocks Get Drilled at TheStreet
07:00AM  The Trader Daily: Lots of Stocks Get Drilled
May-09-16 06:24PM  Healthcare, Biotech SPDR Indexes Gain on May 9 as US Dollar Rises
04:21PM  Why Celldex Therapeutics, Inc. Popped Today at Motley Fool
12:08PM  IHI Bucks the Downward Trend for the Week Ending May 6
May-06-16 10:07AM  Inside XBIs Mid Caps: Ionis Crashes on 1Q16 Earnings Report Market Realist
May-05-16 05:56PM  Inside XBIs Large Caps: Incyte Pulls Down Large Caps on Earnings Concerns Market Realist
09:17AM  How beaten-up Mr. Market still could rise up to a new high at MarketWatch
May-04-16 06:07PM  Inside Soliriss Continued Growth Momentum Market Realist
04:13PM  [$$] Sarepta: A High-Risk, High-Return Trade at Barrons.com
02:05PM  XBIs Mid Caps: Ionis Gives Update on Nusinersen Phase 2 Study Market Realist
02:04PM  Ioniss Metabolic Segment: Phase I and Phase II Studies Market Realist
Apr-28-16 04:56PM  Is XBI Heading Back to Where It Started in April? Market Realist
03:04AM  Opportunities For Xtandi, Medivations Key Drug Market Realist
Apr-27-16 06:08PM  Energy-Related Stocks Rose after FOMC Decision Market Realist
Apr-25-16 09:00AM  Trader's Notebook: Responding to the Move in Dollar Futures at TheStreet
Apr-22-16 09:00AM  Trader's Notebook: Searching for Bullish Excess in the Banks at TheStreet
Apr-21-16 04:51PM  Rising Dollar Offsets Crude Prices as Major SPDR Indexes Fall Market Realist
11:06AM  XBIs Large Caps: BioMarin Gives Update on Gene Therapy Study Market Realist
11:02AM  How Does XBI Compare to Its 100-Day Moving Average? Market Realist
Apr-19-16 05:40PM  SPDR Indexes across Energy and Gold Rise on Increase in Commodities
09:06AM  What Do Analysts Recommend for Medivation?
07:10AM  Return Of The Mack: This Biotech ETF Is Back
Apr-18-16 05:18PM  Recovery in Crude Prices Lifts Energy and Healthcare SPDR Indexes
Apr-15-16 10:39AM  XBI Holdings Finished Strong as Market Bounced Back on April 13
Apr-14-16 04:56PM  US Dollar Is Strong despite Inflation Releasing below Forecast
02:46PM  Analyst Estimates for Ionis Pharmaceuticals 2016 Revenue
Apr-11-16 03:14PM  Large-Cap News: Edwards Surged on SAPIENT 3 TAVR Data
03:14PM  Among Biotechnology ETFs, XBI Dominated the 1st Week of April
Apr-09-16 12:06AM  XBI Mid Caps: Alnylam to Present at Needham Healthcare Conference
Apr-08-16 11:18PM  Last Week's Best Healthcare ETF at Motley Fool
Apr-07-16 04:07PM  Incyte Continues Its Growth Spree in 2015
03:04PM  XBI Large Caps: Incyte Signs Deal with Eli Lilly
12:30PM  A Leader-Laggard Long-Short ETF Pair Trade
11:30AM  Biotech Regain Health: ETFs to Prescribe
Apr-06-16 08:15AM  Inklings Of Upside For A Leveraged Biotech ETF +7.02%
Apr-05-16 03:02PM  US Markets Fall despite Rising Non-Manufacturing PMI
02:50PM  Dont Buy The Greatest Fools Theory Of Investment Value
10:36AM  Biotechnology ETFs: Who Were the Top Performers Last Week?
09:40AM  Broad weakness at open: Pisani
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology industry group of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.